146 related articles for article (PubMed ID: 37060728)
1. A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.
Lu J; Chen J; Lin Z; Liu Q; Zhong C; Cai Z; Jia Z; Zhong W; Liang Y; Cai C
Transl Oncol; 2023 Jul; 33():101670. PubMed ID: 37060728
[TBL] [Abstract][Full Text] [Related]
2. N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.
Liang Y; Yin W; Cai Z; Luo H; Liu Q; Zhong C; Chen J; Lin Z; Huang Y; Liang Z; Deng J; Zhong W; Cai C; Lu J
Hum Genet; 2023 Sep; ():. PubMed ID: 37758909
[TBL] [Abstract][Full Text] [Related]
3. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
4. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
5. Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.
Lin G; Wang H; Wu Y; Wang K; Li G
Front Mol Biosci; 2021; 8():682471. PubMed ID: 34295922
[No Abstract] [Full Text] [Related]
6. Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.
Liu J; Zhang W; Wang J; Lv Z; Xia H; Zhang Z; Zhang Y; Wang J
J Cancer Res Clin Oncol; 2023 May; 149(5):1969-1983. PubMed ID: 35731271
[TBL] [Abstract][Full Text] [Related]
7. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
8. The N6-Methyladenosine Features of mRNA and Aberrant Expression of m6A Modified Genes in Gastric Cancer and Their Potential Impact on the Risk and Prognosis.
Sang L; Sun L; Wang A; Zhang H; Yuan Y
Front Genet; 2020; 11():561566. PubMed ID: 33329697
[TBL] [Abstract][Full Text] [Related]
9. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of transcriptome-wide N6-methyladenosine methylomes in the Barrett's esophagus in rats.
Zou K; Dong H; Li M; Zhang Y; Zhang K; Song D; Chu C
Genomics; 2023 Sep; 115(5):110687. PubMed ID: 37454940
[TBL] [Abstract][Full Text] [Related]
11. M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy.
Zhong C; Long Z; Yang T; Wang S; Zhong W; Hu F; Teoh JY; Lu J; Mao X
Int J Biol Sci; 2023; 19(5):1543-1563. PubMed ID: 37056926
[TBL] [Abstract][Full Text] [Related]
12. Identification and comparison of m6A modifications in glioblastoma non-coding RNAs with MeRIP-seq and Nanopore dRNA-seq.
Krusnauskas R; Stakaitis R; Steponaitis G; Almstrup K; Vaitkiene P
Epigenetics; 2023 Dec; 18(1):2163365. PubMed ID: 36597408
[TBL] [Abstract][Full Text] [Related]
13. Validated Impacts of N6-Methyladenosine Methylated mRNAs on Apoptosis and Angiogenesis in Myocardial Infarction Based on MeRIP-Seq Analysis.
Zhang Y; Hua W; Dang Y; Cheng Y; Wang J; Zhang X; Teng M; Wang S; Zhang M; Kong Z; Lu X; Zheng Y
Front Mol Biosci; 2021; 8():789923. PubMed ID: 35155564
[No Abstract] [Full Text] [Related]
14. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
15. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of the Transcriptome-wide m6A Methylome in Lung Adenocarcinoma by MeRIP Sequencing.
Mao W; Yu Q; Wang K; Ma Q; Zheng Y; Zhang G; Luo W; Wang N; Wang Y
Front Oncol; 2022; 12():791332. PubMed ID: 35903698
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis and Functional Characteristics of Differential Expression of N6-Methyladenosine Methylation Modification in the Whole Transcriptome of Rheumatoid Arthritis.
Wan L; Liu J; Huang C; Zhu Z; Wang K; Sun G; Zhu L; Hu Z
Mediators Inflamm; 2022; 2022():4766992. PubMed ID: 36330380
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Novel Three Hub Long Noncoding RNAs With m6A Modification Signature in Low-Grade Gliomas.
Nguyen QH; Nguyen T; Le DH
Front Mol Biosci; 2022; 9():801931. PubMed ID: 35237657
[TBL] [Abstract][Full Text] [Related]
19. N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma.
Sun J; Ping Y; Huang J; Zeng B; Ji P; Li D
Front Cell Dev Biol; 2021; 9():705962. PubMed ID: 34422827
[TBL] [Abstract][Full Text] [Related]
20. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
Huang X; Wang HF; Huang S
Front Genet; 2022; 13():906880. PubMed ID: 36061188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
